vs
AVINO SILVER & GOLD MINES LTD（ASM）与Journey Medical Corp（DERM）财务数据对比。点击上方公司名可切换其他公司
AVINO SILVER & GOLD MINES LTD的季度营收约是Journey Medical Corp的1.3倍（$21.0M vs $16.1M），AVINO SILVER & GOLD MINES LTD净利率更高（36.6% vs -7.8%，领先44.4%），AVINO SILVER & GOLD MINES LTD同比增速更快（44.0% vs 27.3%），过去两年AVINO SILVER & GOLD MINES LTD的营收复合增速更高（51.1% vs 11.0%）
阿维诺金银矿业有限公司是一家加拿大矿业企业，主要从事银、金、铜等贵金属及基本金属的勘探、开发与生产，核心运营资产为位于墨西哥杜兰戈州的旗舰阿维诺矿区，产品供应全球大宗商品市场。
Journey Medical Corp是一家处于商业化阶段的生物制药企业，专注于皮肤病治疗领域，研发、生产并销售处方及非处方皮肤用药，覆盖痤疮、特应性皮炎、皮肤真菌感染等适应症，主要服务美国市场的医疗机构与患者。
ASM vs DERM — 直观对比
营收规模更大
ASM
是对方的1.3倍
$16.1M
营收增速更快
ASM
高出16.7%
27.3%
净利率更高
ASM
高出44.4%
-7.8%
两年增速更快
ASM
近两年复合增速
11.0%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $21.0M | $16.1M |
| 净利润 | $7.7M | $-1.2M |
| 毛利率 | 47.1% | — |
| 营业利润率 | — | -2.8% |
| 净利率 | 36.6% | -7.8% |
| 营收同比 | 44.0% | 27.3% |
| 净利润同比 | 558.9% | -182.0% |
| 每股收益（稀释后） | $0.05 | $-0.04 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASMDERM
| Q4 25 | — | $16.1M | ||
| Q3 25 | $21.0M | $17.0M | ||
| Q2 25 | $21.8M | $15.0M | ||
| Q1 25 | $18.8M | $13.1M | ||
| Q4 24 | — | $12.6M | ||
| Q3 24 | $14.6M | $14.6M | ||
| Q2 24 | $14.8M | $14.9M | ||
| Q1 24 | $12.4M | $13.0M |
净利润ASMDERM
| Q4 25 | — | $-1.2M | ||
| Q3 25 | $7.7M | $-2.3M | ||
| Q2 25 | $2.9M | $-3.8M | ||
| Q1 25 | $5.6M | $-4.1M | ||
| Q4 24 | — | $1.5M | ||
| Q3 24 | $1.2M | $-2.4M | ||
| Q2 24 | $1.2M | $-3.4M | ||
| Q1 24 | $599.0K | $-10.4M |
毛利率ASMDERM
| Q4 25 | — | — | ||
| Q3 25 | 47.1% | — | ||
| Q2 25 | 46.9% | — | ||
| Q1 25 | 56.1% | — | ||
| Q4 24 | — | 82.3% | ||
| Q3 24 | 39.1% | 63.9% | ||
| Q2 24 | 31.8% | 56.0% | ||
| Q1 24 | 18.9% | 47.7% |
营业利润率ASMDERM
| Q4 25 | — | -2.8% | ||
| Q3 25 | — | -9.0% | ||
| Q2 25 | — | -19.2% | ||
| Q1 25 | — | -25.3% | ||
| Q4 24 | — | 17.7% | ||
| Q3 24 | — | -19.8% | ||
| Q2 24 | — | -19.7% | ||
| Q1 24 | — | -77.4% |
净利率ASMDERM
| Q4 25 | — | -7.8% | ||
| Q3 25 | 36.6% | -13.6% | ||
| Q2 25 | 13.1% | -25.3% | ||
| Q1 25 | 29.8% | -31.0% | ||
| Q4 24 | — | 12.1% | ||
| Q3 24 | 8.0% | -16.3% | ||
| Q2 24 | 8.4% | -22.6% | ||
| Q1 24 | 4.8% | -80.1% |
每股收益（稀释后）ASMDERM
| Q4 25 | — | $-0.04 | ||
| Q3 25 | $0.05 | $-0.09 | ||
| Q2 25 | $0.02 | $-0.16 | ||
| Q1 25 | $0.04 | $-0.18 | ||
| Q4 24 | — | $0.10 | ||
| Q3 24 | $0.01 | $-0.12 | ||
| Q2 24 | $0.01 | $-0.17 | ||
| Q1 24 | $0.00 | $-0.53 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $57.3M | $24.1M |
| 总债务越低越好 | — | $25.3M |
| 股东权益账面价值 | $182.1M | $31.9M |
| 总资产 | $221.9M | $94.6M |
| 负债/权益比越低杠杆越低 | — | 0.79× |
8季度趋势，按日历期对齐
现金及短期投资ASMDERM
| Q4 25 | — | $24.1M | ||
| Q3 25 | $57.3M | $24.9M | ||
| Q2 25 | $37.3M | $20.3M | ||
| Q1 25 | $26.6M | $21.1M | ||
| Q4 24 | — | $20.3M | ||
| Q3 24 | $7.8M | $22.5M | ||
| Q2 24 | $5.3M | $23.9M | ||
| Q1 24 | $3.5M | $24.1M |
总债务ASMDERM
| Q4 25 | — | $25.3M | ||
| Q3 25 | — | $25.2M | ||
| Q2 25 | — | $25.1M | ||
| Q1 25 | — | $25.0M | ||
| Q4 24 | — | $24.9M | ||
| Q3 24 | — | $19.8M | ||
| Q2 24 | — | $19.7M | ||
| Q1 24 | — | $14.7M |
股东权益ASMDERM
| Q4 25 | — | $31.9M | ||
| Q3 25 | $182.1M | $25.9M | ||
| Q2 25 | $144.8M | $19.2M | ||
| Q1 25 | $132.3M | $21.5M | ||
| Q4 24 | — | $20.1M | ||
| Q3 24 | $114.5M | $10.9M | ||
| Q2 24 | $112.2M | $11.3M | ||
| Q1 24 | $107.8M | $13.0M |
总资产ASMDERM
| Q4 25 | — | $94.6M | ||
| Q3 25 | $221.9M | $85.2M | ||
| Q2 25 | $174.7M | $81.2M | ||
| Q1 25 | $157.7M | $85.0M | ||
| Q4 24 | — | $80.2M | ||
| Q3 24 | $135.4M | $64.0M | ||
| Q2 24 | $133.7M | $65.2M | ||
| Q1 24 | $128.6M | $66.6M |
负债/权益比ASMDERM
| Q4 25 | — | 0.79× | ||
| Q3 25 | — | 0.97× | ||
| Q2 25 | — | 1.30× | ||
| Q1 25 | — | 1.16× | ||
| Q4 24 | — | 1.24× | ||
| Q3 24 | — | 1.81× | ||
| Q2 24 | — | 1.75× | ||
| Q1 24 | — | 1.13× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $8.3M | $-6.3M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | 1.08× | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ASMDERM
| Q4 25 | — | $-6.3M | ||
| Q3 25 | $8.3M | $-2.4M | ||
| Q2 25 | $8.3M | $-942.0K | ||
| Q1 25 | $758.0K | $-2.8M | ||
| Q4 24 | — | $2.2M | ||
| Q3 24 | $4.1M | $-1.2M | ||
| Q2 24 | $1.1M | $-5.2M | ||
| Q1 24 | $2.3M | $-5.0M |
现金转化率ASMDERM
| Q4 25 | — | — | ||
| Q3 25 | 1.08× | — | ||
| Q2 25 | 2.92× | — | ||
| Q1 25 | 0.13× | — | ||
| Q4 24 | — | 1.46× | ||
| Q3 24 | 3.55× | — | ||
| Q2 24 | 0.87× | — | ||
| Q1 24 | 3.92× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASM
暂无分部数据
DERM
| Qbrexza | $5.5M | 35% |
| Emrosi | $5.0M | 31% |
| Accutane | $3.1M | 19% |
| Other | $2.5M | 15% |
